The surgeons still want to operate. The patients still need new hips and knees. The insurers are saying no. That's the week. Stryker, the bellwether for the whole recon market, missed its own expectations and pinned the hip and knee slowdown on insurance affordability and preauthorization denials. Two days earlier, the biggest check in ortho went to surgery centers, not implants: a $5.7B take-private of Surgery Partners. And Stryker quietly closed a rotator cuff deal that tells you where it thinks the growth actually is. Put those together and you get the theme: in orthopedics right now, whoever controls the approval and the site of care controls the volume. The implant is downstream of both. Let's get into it. 1/ Stryker: The Bellwether Blinks, and Blames the Payer Stryker reported Q3 on Oct 29. Key Figures:
Q3 sales rose 7.7% to $6.5B; adjusted EPS rose 10.3% to $3.52. Full-year organic growth guidance adjusted to 6.5–7.0%; adjusted EPS guidance to $14.80–$14.90. US hips fell 0.6%; US knees grew only 1.3%. Ortho Tech grew 15.8%; Trauma & Extremities grew 5.3%. Booked a $293M goodwill impairment and added $3.0B to its buyback.
The Takeaway: US hips went backwards at the comp...
Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !

